By David Bautz, PhD
NASDAQ: ESLA
READ THE FULL ESLA RESEARCH REPORT
Initiating Coverage
We are initiating coverage of Estrella Immunopharma (NASDAQ: ESLA) with a valuation of $12.00 per share and a thesis centered on the potential for the company to emerge as one of the next generation of differentiated CAR-T innovators following the value creation recently demonstrated by Arcellx, Inc. and its acquisition by Gilead Sciences for approximately $7.8 billion. Estrella is developing next-generation engineered T-cell therapies designed to address several of the key limitations associated with conventional CAR-T constructs, including excessive immune activation, treatment-related toxicity, and loss of durable T-cell activity. The company’s technology platform, ARTEMIS®, combines antibody-based antigen recognition with physiologic T-cell receptor signaling, enabling a more controlled form of T-cell activation that may improve the therapeutic window of engineered T-cell therapies.
Estrella’s lead program, EB103, is a CD19-directed ARTEMIS engineered T-cell therapy being developed for relapsed or refractory B-cell malignancies. CD19 remains one of the most clinically validated targets in hematologic oncology, but meaningful opportunities remain to improve the safety, durability, and scalability of CD19-directed CAR-T treatments. Early clinical data presented from the Phase 1/2 STARLIGHT-1 trial demonstrated encouraging efficacy and safety signals, including a 100% complete response rate at dose level 2 with no ≥ Grade 3 cytokine release syndrome, suggesting EB103 may offer a differentiated safety and efficacy profile within this well-established therapeutic class.
Next-generation engineered T-cell platform targeting known CAR-T limitations
Estrella’s ARTEMIS platform separates antigen recognition from intracellular costimulatory signaling, allowing engineered T cells to activate through physiologic T-cell receptor pathways rather than conventional CAR signaling domains. This architecture is designed to produce a more controlled immune response that may potentially improve both safety and durability of response compared to first-generation CAR-T therapies.
Encouraging early clinical data supporting platform differentiation
Early clinical observations from EB103 have demonstrated durable complete responses in patients with relapsed or refractory B-cell lymphoma along with a low incidence of high-grade cytokine release syndrome and immune effector cell–associated neurotoxicity. Results from the Phase 1/2 STARLIGHT-1 study showed a 100% complete response rate at dose level 2, despite approximately 80% of treated patients meeting high-risk disease criteria, providing early clinical support for the ARTEMIS platform.
Strong commercial precedent for CD19-directed engineered T-cell therapies
Multiple approved CD19 CAR-T products have already demonstrated the clinical and commercial value of this target across B-cell malignancies. As next-generation technologies seek to improve safety and durability, companies capable of delivering differentiated CAR-T performance may attract substantial strategic interest, as illustrated by the recent multi-billion-dollar acquisition of Arcellx by Gilead Sciences. Estrella’s platform-driven approach to improving engineered T-cell signaling may position the company to participate in the next wave of value creation within the CAR-T sector.
Valuation
We value Estrella using a probability-adjusted discounted cash flow model that takes into account revenues from the sale of EB103 in B-cell malignancies. While not currently a part of the model, we view EB104 and the company’s ‘mark-and-kill’ platform as offering potential upside to our valuation. We estimate there are approximately 77,000 patients diagnosed with non-Hodgkin lymphoma (NHL) annually in the United States, while epidemiology data from GLOBOCAN database suggests roughly 120,000 additional cases occur each year in Europe. Despite advances in frontline chemotherapy, approximately 30-40% of patients experience relapsed or refractory disease following first-line treatment, and a meaningful subset ultimately progress to third-line or later therapy. Applying these progression rates suggests that approximately 30,000-40,000 patients across the U.S. and E.U. may become eligible for third-line or later therapies each year, representing the core addressable population for CD19-directed cell therapies. We model for EB103 to cost $350,000 per year and to have peak worldwide revenues of just over $2 billion in 2037. Using a 13% discount rate and a 33% probability of approval leads to a net present value for EB103 of $703 million.
Combining the net present value for EB103 with the company’s current cash position (~$5 million) and the potential cash from warrant exercises (~$36 million) leads to a net present value for the company of $744 million. The fully diluted share count currently stands at 52.9 million, and we add 10 million shares for potential dilution, which leads to a valuation of $12.00 per share.
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives payments totaling a maximum fee of up to $50,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.